GregoryAnthonyYanikMD

Pediatric Hematology & Oncology • Ann Arbor, MI

Professor, Pediatrics & Communicable Diseases, University of Michigan Medical School

Join to view full profile

Dr. Yanik is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Yanik's full profile

Already have an account?

Office
1540 E Hospital Dr
Ann Arbor, MI 48109
Phone+1 734-936-9814

Fax+1 734-232-7580

Education & Training

Cincinnati Children's Hospital Medical CenterFellowship, Pediatric Hematology/Oncology, 1988 - 1991
Corewell Health East Beaumont (Royal Oak)Residency, Internal Medicine, 1984 - 1987
Corewell Health East Beaumont (Royal Oak)Internship, Transitional Year, 1983 - 1984
Wayne State University School of MedicineClass of 1983

Certifications & Licensure

MI State Medical License 1984 - 2026
OH State Medical License 1988 - 1992
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation Start of enrollment: 2004 Mar 01
Completed
Phase 1
Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant Start of enrollment: 2003 Oct 01
Completed
Phase 2
N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma Start of enrollment: 2005 Sep 01
Completed
Phase 2
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant Start of enrollment: 2006 Apr 01
Completed
Phase 2
Effectiveness of Etanercept for Idiopathic Pneumonia Syndrome Following Stem Cell Transplantation (BMT CTN 0403) Start of enrollment: 2007 Aug 01
Completed
Phase 3
Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia Start of enrollment: 2007 Mar 01
Completed
Phase 2
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma Start of enrollment: 2009 Dec 01
Completed
Phase 1
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma Start of enrollment: 2010 Mar 01
Completed
Phase 1
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma Start of enrollment: 2013 Feb 04
Active, not recruiting
Phase 1
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan Start of enrollment: 2014 Jan 16
Active, not recruiting
Phase 1
131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat Start of enrollment: 2014 Jul 01
Completed
Phase 2
Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS) Start of enrollment: 2020 Oct 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

3222 citations
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Shannon L. Maude, Theodore W. Laetsch, Jochen Buechner, S. Rives, Michael Boyer
The New England Journal of Medicine. 2018-01-31
100 citations
Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell ...
Sung Won Choi, Thomas Braun, Lawrence Chang, James L.M. Ferrara, Attaphol Pawarode
The Lancet. Oncology. 2014-01-01
70 citations
A critical role for CCR2/MCP-1 interactions in the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation
Gerhard C. Hildebrandt, Ulrich Duffner, Krystyna M. Olkiewicz, Leigh A. Corrion, Nicole E. Willmarth
Blood. 2004-03-15

Journal Articles

Related Peripheral Blood Stem Cell Donors Experience More Severe Symptoms and Less Complete Recovery at 1-Year Compared to Unrelated Donors
Parameswaran N Hari, David A Jacobsohn, Joseph P McGuirk, Mary M Horowitz, Walter Longo, Thomas Spitzer, Daniel J Weisdorf, Shahram Mori, David C Delgado, Marcie L Ric..., Haematologica
Veno-Occlusive Disease After High-Dose Busulfan–Melphalan in Neuroblastoma
Gregory Yanik, Morris Kletzel, Stephan Grupp, David Jacobsohn, Christopher C Dvorak, Alix E Seif, Mark Ranalli, Haydar Frangoul, Nature

Abstracts/Posters

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World E...
Gregory Yanik, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Molecular Detection of Minimal Residual Disease Precedes Morphological Relapse and Could be Used to Identify Relapse in Pediatric and Young Adult B-Cell Acute Lymphobl...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

H. Pylori May Hinder Efficacy of Immune Checkpoint InhibitorsAugust 4th, 2021
U-M Rogel Cancer Center First in Michigan to Offer All FDA Approved Car T-cell TherapiesMay 23rd, 2018
Mott Poised to Be Among First in the Nation to Offer Groundbreaking CAR-T Cell Therapy for Childhood LeukemiaAugust 31st, 2017

Grant Support

MIBG W/ Intensive Chemotheryapy &Autologous Stem Cell Rescue For NeuroblastemaNational Center For Research Resources2007
Etanercept For Treatment Of Sub-Acute Pulm Dysfunction After Allogeneic BMTNational Center For Research Resources2007
(MIBG) With Intensive Chemotheryapy And Autologous Stem Cell Rescue For NeuroblaNational Center For Research Resources2006
131-I-Metaiodobenzylguanidine (131i-Mibg) Therapy For Refractory NeuroblastomaNational Center For Research Resources2004–2006
131-1 MIBG In Combination With Chemotherapy For NeuroblastomaNational Center For Research Resources2000–2002